Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO traded down $1.37 during trading hours on Thursday, reaching $78.17. The company’s stock had a trading volume of 1,804,089 shares, compared to its average volume of 2,911,446. The firm has a market capitalization of $15.23 billion, a price-to-earnings ratio of -25.71 and a beta of 0.97. The firm has a 50-day simple moving average of $69.92 and a 200-day simple moving average of $72.79. BridgeBio Pharma, Inc. has a 1 year low of $62.50 and a 1 year high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. The business’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) EPS. Equities analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Weiss Ratings lowered BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. TD Cowen dropped their price target on BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Morgan Stanley lifted their price target on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company upped their price objective on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Nineteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.26.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently modified their holdings of the stock. First Bank & Trust raised its holdings in BridgeBio Pharma by 1.6% in the second quarter. First Bank & Trust now owns 8,797 shares of the company’s stock worth $655,000 after buying an additional 142 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock worth $29,000 after buying an additional 157 shares in the last quarter. Covestor Ltd grew its holdings in shares of BridgeBio Pharma by 7.6% during the third quarter. Covestor Ltd now owns 2,252 shares of the company’s stock valued at $149,000 after buying an additional 159 shares during the last quarter. North Dakota State Investment Board grew its holdings in shares of BridgeBio Pharma by 3.9% during the third quarter. North Dakota State Investment Board now owns 5,177 shares of the company’s stock valued at $341,000 after buying an additional 196 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of BridgeBio Pharma by 13.8% during the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after acquiring an additional 199 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $72.85, for a total transaction of $145,700.00. Following the sale, the chief accounting officer owned 120,687 shares of the company’s stock, valued at $8,792,047.95. This trade represents a 1.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 34,980 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the completion of the sale, the chief executive officer owned 243,327 shares of the company’s stock, valued at $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 56,980 shares of company stock worth $4,563,699 over the last ninety days. 14.23% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.